InsiderTrades.com logo

ALZN Insider Trading

Insider Ownership Percentage: 30.21%
Insider Buying (Last 12 Months): $13,319.64
Insider Selling (Last 12 Months): $0.00

Alzamend Neuro Insider Trading History Chart

This chart shows the insider buying and selling history at Alzamend Neuro by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alzamend Neuro Share Price & Price History

Current Price: $3.53
Price Change: ▲ Price Increase of +0.36 (11.36%)
As of 07/16/2025 05:00 PM ET

This chart shows the closing price history over time for ALZN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Alzamend Neuro Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/26/2025William B HorneDirectorBuy370$8.91$3,296.703,333View SEC Filing Icon  
3/20/2025William B HorneDirectorBuy555$8.82$4,895.102,962View SEC Filing Icon  
3/18/2025Milton C. Ault IIIDirectorBuy555$8.64$4,795.209,152View SEC Filing Icon  
3/12/2025Milton C. Ault IIIDirectorBuy11$6.12$67.328,596View SEC Filing Icon  
8/6/2024Milton C. Ault IIIDirectorBuy8$24.75$198.008,585View SEC Filing Icon  
7/31/2024Milton C. Ault IIIDirectorBuy2$33.66$67.328,577View SEC Filing Icon  
4/19/2024Milton C. Ault IIIDirectorBuy11$62.10$683.108,574View SEC Filing Icon  
4/1/2024Milton C. Ault IIIDirectorBuy3$81.90$245.708,563View SEC Filing Icon  
1/5/2024Milton C. Ault IIIDirectorBuy55$91.80$5,049.008,537View SEC Filing Icon  
12/26/2023Milton C. Ault IIIMajor ShareholderBuy5$81.00$405.00289View SEC Filing Icon  
12/22/2023Milton C. Ault IIIMajor ShareholderBuy2$82.80$165.601,854View SEC Filing Icon  
9/26/2023David J KatzoffCFOBuy39$256.50$10,003.5060View SEC Filing Icon  
5/24/2023Milton C. Ault IIIMajor ShareholderBuy13$796.50$10,354.50283View SEC Filing Icon  
4/28/2023Stephan JackmanCEOBuy27$729.00$19,683.0033View SEC Filing Icon  
3/22/2023Lynne Fahey McgrathDirectorBuy7$580.50$4,063.507View SEC Filing Icon  
3/16/2023Milton C. Ault IIIMajor ShareholderBuy2$675.00$1,350.008,188View SEC Filing Icon  
2/15/2023Milton C. Ault IIIMajor ShareholderBuy0$810.00$0.008,185View SEC Filing Icon  
12/27/2022Milton C. Ault IIIMajor ShareholderBuy0$796.50$0.008,182View SEC Filing Icon  
11/18/2022Milton C. Ault IIIMajor ShareholderBuy0$1,741.50$0.008,176View SEC Filing Icon  
10/31/2022Milton C. Ault IIIMajor ShareholderBuy4$1,606.50$6,426.007,483View SEC Filing Icon  
10/12/2022Milton C. Ault IIIMajor ShareholderBuy1$1,660.50$1,660.507,479View SEC Filing Icon  
10/6/2022Milton C. Ault IIIMajor ShareholderBuy0$1,930.50$0.007,477View SEC Filing Icon  
9/29/2022Milton C. Ault IIIMajor ShareholderBuy2$1,606.50$3,213.007,476View SEC Filing Icon  
9/19/2022Stephan JackmanCEOBuy6$1,660.50$9,963.006View SEC Filing Icon  
9/14/2022David J KatzoffCFOBuy7$1,498.50$10,489.5020View SEC Filing Icon  
8/25/2022Milton C. Ault IIIMajor ShareholderBuy3$1,296.00$3,888.007,413View SEC Filing Icon  
8/22/2022Milton C. Ault IIIMajor ShareholderBuy26$1,309.50$34,047.007,409View SEC Filing Icon  
8/15/2022Milton C. Ault IIIMajor ShareholderBuy10$1,431.00$14,310.007,371View SEC Filing Icon  
8/3/2022Milton C. Ault IIIMajor ShareholderBuy1$1,282.50$1,282.507,360View SEC Filing Icon  
7/27/2022Milton C. Ault IIIMajor ShareholderBuy4$1,174.50$4,698.007,359View SEC Filing Icon  
7/22/2022Milton C. Ault IIIMajor ShareholderBuy1$1,228.50$1,228.507,354View SEC Filing Icon  
7/18/2022Milton C. Ault IIIMajor ShareholderBuy7$1,323.00$9,261.007,353View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Alzamend Neuro (NASDAQ:ALZN)

49.61% of Alzamend Neuro stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ALZN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Alzamend Neuro Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/17/2025Citadel Advisors LLC30,638$36K0.0%N/A0.564%Search for SEC Filing on Google Icon
2/12/2025Geode Capital Management LLC33,540$39K0.0%N/A0.618%Search for SEC Filing on Google Icon
5/20/2024Virtu Financial LLC26,482$26K0.0%N/A0.385%Search for SEC Filing on Google Icon
2/2/2024Truist Financial Corp154,327$0.14M0.0%-93.3%2.168%Search for SEC Filing on Google Icon
5/11/2022RFG Advisory LLC250,000$0.31M0.0%N/A0.277%Search for SEC Filing on Google Icon
5/9/2022Qube Research & Technologies Ltd78,465$97K0.0%N/A0.087%Search for SEC Filing on Google Icon
4/22/2022Truist Financial Corp2,314,907$2.85M0.0%N/A2.569%Search for SEC Filing on Google Icon
1/31/2022Commonwealth Equity Services LLC116,666$0.22M0.0%N/A0.131%Search for SEC Filing on Google Icon
11/16/2021Schonfeld Strategic Advisors LLC31,600$97K0.0%N/A0.036%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Investments LP172,913$0.53M0.0%N/A0.199%Search for SEC Filing on Google Icon
11/16/2021Warberg Asset Management LLC14,000$43K0.0%N/A0.016%Search for SEC Filing on Google Icon
11/15/2021Sassicaia Capital Advisers LLC93,762$0.29M0.8%N/A0.108%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC15,402$0.14M0.0%N/A0.018%Search for SEC Filing on Google Icon
8/16/2021Cubist Systematic Strategies LLC23,672$0.21M0.0%N/A0.028%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC44,600$0.39M0.0%N/A0.052%Search for SEC Filing on Google Icon
8/11/2021Susquehanna International Group LLP57,030$0.50M0.0%N/A0.067%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Alzamend Neuro logo
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Read More on Alzamend Neuro

Today's Range

Now: $3.53
Low: $3.16
High: $3.60

50 Day Range

MA: $3.46
Low: $2.88
High: $5.92

52 Week Range

Now: $3.53
Low: $2.75
High: $135.54

Volume

479,957 shs

Average Volume

473,229 shs

Market Capitalization

$2.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Alzamend Neuro?

Alzamend Neuro's top insider shareholders include:
  1. Milton C Ault III (Director)
  2. William B Horne (Director)
  3. Milton C Ault III (Major Shareholder)
  4. David J Katzoff (CFO)
Learn More about top insider investors at Alzamend Neuro.